PAHC Phibro Animal Health Corporation

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shareholders of Phibro Animal Health would probably like to forget the past six months even happened. The stock dropped 38.5% and now trades at $34.11. This may have investors wondering how to approach the situation.

Let’s dig into the relative performance of Phibro Animal Health (NASDAQ:PAHC) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season.

PAHC vs. HAE: Which Stock Is the Better Value Option?

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

DiamondRock, Vertiv, Mueller Water Products and Phibro have been highlighted in this Screen of The Week article.

The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Phibro (PAHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Phibro Animal Health earnings and guidance set the tone Phibro Animal Health (PAHC) drew investor attention after issuing earnings guidance for the fiscal year ending June 30, 2027, alongside reporting fourth quarter and full year 2026 results. The company now projects 2027 net sales of US$1.55b to US$1.60b and net income of US$122 million to US$132 million. Expected diluted EPS is US$2.98 to US$3.22. These figures follow 2026 sales of US$1,518.09 million and net income of US$99.72...

PAHC vs. LMAT: Which Stock Is the Better Value Option?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Evaluate Phibro's (PAHC) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Phibro Animal Health (NASDAQ:PAHC) closed out fiscal 2026 with numbers that speak for themselves. Full-year net sales topped $1.5 billion, adjusted EBITDA climbed 39% to $255 million, and adjusted diluted earnings per share jumped 48% to $3.22. The results, covering the quarter and year ended June 30, mark the first complete fiscal year since the […]

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Adjusted EBITDA surged 39% as the company integrated its acquired medicated feed additive portfolio.

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 4.8% year on year to $396.7 million. The company’s full-year revenue guidance of $1.58 billion at the midpoint came in 1.7% above analysts’ estimates. Its GAAP profit of $0.53 per share was 17.3% below analysts’ consensus estimates.

Phibro Animal Health Corp (PAHC) posts record FY2026 results with 39% adjusted EBITDA growth, while navigating Brazil regulatory uncertainty and executing strategic manufacturing optimization.

Phibro Animal Health (NASDAQ:PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phi

Moby summary of Phibro Animal Health Corporation's Q4 2026 earnings call

Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Phibro (PAHC) delivered earnings and revenue surprises of +18.06% and +8.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) announced better-than-expected revenue in Q2 CY2026, with sales up 4.8% year on year to $396.7 million. The company’s full-year revenue guidance of $1.58 billion at the midpoint came in 1.9% above analysts’ estimates. Its non-GAAP profit of $0.85 per share was 17.1% above analysts’ consensus estimates.

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) will be reporting earnings this Wednesday afternoon. Here’s what investors should know.

Besides Wall Street's top-and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

Phibro Animal Health has delivered a very strong 149.1% return over the past 3 years, yet the current valuation checks paint a more mixed picture rather than a straightforward bargain or clear overpricing. Phibro Animal Health's 149.1% three year return shows shareholders have already seen very large gains, which raises the bar for any new buyers looking for further upside. Future expectations around margins and cash flow from its animal health portfolio can support today’s price. However,...

Phibro Animal Health (PAHC) is approaching a key disclosure date, with fourth quarter and full year 2026 results scheduled for release on August 26 after the market close, followed by a conference call on August 27. See our latest analysis for Phibro Animal Health. The upcoming earnings announcement comes after a mixed year for Phibro Animal Health, with the share price at US$35.44, a 1 month share price return of 7.23% and year to date share price return declining 4.99%, while the 3 year...

Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -100.00% and -0.34%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Align Technology shares rise after Q2 earnings and revenues beat estimates, fueled by record Clear Aligner shipments and wider non-GAAP margins.

Tilray Brands (TLRY) delivered earnings and revenue surprises of -2,050.00% and +9.14%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

PAHC vs. SYK: Which Stock Is the Better Value Option?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.